Indirect Participation in the Equity Value of HLB's Key Affiliates... Diversifying Investment Exposure
Integration of the Drug Business and Improved Management Efficiency Expected to Strengthen Business Competitiveness and Financial Stability

HLB Life Science to Transform Business Structure Through Merger with HLB... Expand Mid- to Long-Term Growth Base View original image

HLB Life Science plans to transform its business structure and expand the foundation for medium- to long-term growth through a merger with HLB. The strategy is to move beyond a structure centered on regional business rights for rivoceranib and transition to one in which shareholders share in the value of global drug development and the growth of key affiliates, while enhancing corporate value by integrating business capabilities and improving management efficiency.


The most significant feature of the merger is that it will broaden the range of businesses in which HLB Life Science shareholders have an investment interest.


HLB is the parent company of a group that pursues global drug development and commercialization while holding stakes in key biotech affiliates, and effectively serves as a business holding company. Accordingly, HLB's corporate value is influenced not only by its own drug business but also by the business performance of key affiliates and changes in the value of its equity stakes.


Once the merger is completed, HLB Life Science shareholders will receive 0.0857532 HLB shares for each share they hold, becoming shareholders of the combined company. This will allow them to participate indirectly not only in the value of existing business rights related to rivoceranib but also in changes in the value of HLB's equity stakes resulting from the growth of its key affiliates.


In particular, if drug development and commercialization at HLB's key affiliates make progress, the results could be reflected in the value of HLB's equity stakes and the corporate value of the combined company. This means that HLB Life Science shareholders' investment base will expand from regional business rights for a specific drug to a range of drug pipelines and affiliate businesses.


The foundation for growth in the global drug business will also broaden.


HLB Life Science currently holds exclusive development and sales rights for rivoceranib in South Korea, as well as rights to participate in profits in Japan and Europe. After the merger, these rights will be consolidated under HLB, enabling the company to establish a more efficient operating system spanning drug development, regulatory approval, and commercialization.


HLB Life Science shareholders will also be able to share in the growth of HLB's global drug portfolio through changes in the combined company's corporate value. This portfolio includes Ripicto (lirafugratinib), a bile duct cancer drug that received approval from the U.S. Food and Drug Administration (FDA) in September this year.


Synergies are also expected in business operations and management efficiency.


Integrating the research and development resources and business management functions currently distributed across the two companies could simplify decision-making and reduce duplicated administrative costs. In particular, more efficient allocation of the personnel and resources needed for drug development and commercialization is expected to strengthen business competitiveness and improve the earnings structure.


HLB Life Science's medical supplies and healthcare businesses could also expand into new business opportunities by linking with HLB's existing business base. Integrating the separately operated treasury management and management support functions is also expected to help reduce costs and improve financial efficiency.


The merger is also expected to mark an important turning point in terms of financial stability.


Concerns have been raised that HLB Life Science could be designated as an administrative issue because of the ongoing research and development investment required for drug development and the resulting impact on its earnings.


However, once the merger is completed, HLB Life Science will cease to exist as an independently listed company and will be integrated into HLB. This will also resolve concerns that HLB Life Science could be designated as an administrative issue as a separately listed company.


In addition, integrating the business capabilities and management resources currently distributed across the two companies and reducing duplicated costs are expected to improve financial efficiency and the earnings structure.


The merger is also significant because it is being pursued in a business environment that has changed since last year. HLB entered the drug commercialization stage after securing U.S. FDA approval for Ripicto in September this year, making the need for business integration and its expected benefits more tangible.


However, the extent to which the merger enhances corporate value may vary depending on future drug commercialization results, the business performance of key affiliates, and the level of management efficiency achieved after integration. Whether the merger proceeds will also depend on relevant procedures, including shareholder approval and the scale of the exercise of appraisal rights.



An HLB official said, "This merger is significant because it will give HLB Life Science a new foundation for growth, enabling it to move beyond its existing business structure centered on rivoceranib and share in the value of global drug development and the growth of key affiliates. We will bring together the two companies' business capabilities and improve management efficiency to strengthen our business competitiveness and financial stability and enhance corporate value over the medium to long term."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing